The most useful data you own

The best numbers you will ever work with are not in a book or on a product page. They are your own: your training log, what you actually eat in a week, and your blood results.

Those numbers tell you where the real gains are. Most people who feel flat, recover slowly or struggle with body composition have something basic to fix first. Training that is inconsistent. Protein that is too low. A nutrient deficiency, such as low vitamin D, B12, ferritin or magnesium, that a simple blood test would catch and that food or a targeted supplement can correct. And for some people, an inherited trait that changes what the body needs, which clinically validated genetic testing through a doctor can identify. (Consumer DNA "diet" reports are not the same thing, and most of their claims are weak.)

Get those foundations dialled in and you have a baseline to measure anything else against. Without them, you are guessing, and you are easy to sell to. Which brings us to where this book gets its numbers.

The sentence that changes how you read the book

At the start of the bioregulator chapter, in a short disclaimer, The Complete Guide to Peptides says something remarkable. Most of the dosing information in that section comes from the product listing for each compound on a specific online vendor's website. It then describes that vendor as the easiest and most comprehensive place to find bioregulators, adding that most of them can be bought there.

Read that again with Part 1 in mind. The author writes under an alias. The book includes an affiliate disclosure. And the dosing for roughly a third of the compounds in the book comes from a shop's own product pages, with the shop recommended by name.

That is not a source of dosing information. It is a sales listing. A company selling a product has every reason to recommend taking it, and no obligation to have tested whether its recommended dose does anything.

The introduction's promise

Now compare that with what the book says about itself in its introduction. It lists its goals, including "Accuracy", described as providing evidence-based information validated by peer-reviewed research.

The book contains no reference list. Not one study is cited by author, journal and year anywhere in its entries. The "Research Recommendations" section, which I praised in Part 1, gives you search terms, which is useful, but a search term is not a citation. It tells you where to look, not what the book's claims are based on.

So the book promises peer-reviewed accuracy, and for at least a third of its content, the dosing is openly from a vendor.

Safety claims with nothing behind them

Several bioregulator entries make specific safety claims. Cardiogen is described as having shown excellent safety and tolerability in clinical studies. Cartalax is described as having no significant adverse effects in clinical studies.

Which clinical studies? The book does not say. Given that the dosing is taken from a sales listing, a reader has no way to know whether these safety claims came from actual trials or from the same product pages.

The book contradicts itself

Checking entries against each other turns up errors a careful editor would have caught:

Bonomarlot. Its encyclopedia entry says it comes from liver tissue and supports liver regeneration and detoxification. Later, in the section on treating specific conditions, the same book describes Bonomarlot as supporting bone marrow function and blood cell production. Those are completely different organs.

CJC-1295 with DAC. The DAC attachment lets the peptide bind to albumin in the blood, so this version lasts about a week, which is the whole point of it. This book's entry for CJC-1295 with DAC recommends 100 to 200 micrograms nightly, five days on, two off. That is the dosing pattern usually described for the short-acting version without DAC. Following it with the long-acting version would stack up doses of a drug that is still active from the previous days.

Stacking GLP-1 drugs. The survodutide entry says it can be stacked with tirzepatide or retatrutide. All three act on the GLP-1 receptor. Doubling up on GLP-1 activity raises the risk of severe gastrointestinal effects and has no established benefit. Even the other consumer books reviewed on this blog warn explicitly against combining GLP-1 drugs.

PT-141. The book says it is effective in treating erectile dysfunction. It was studied for that and not approved for it. Its approval is for low sexual desire in premenopausal women.

Humanin. Said to be first discovered in the hypothalamus. It was not, as Part 5 noted.

Retatrutide. Its search recommendation calls it a dual agonist. It is a triple agonist.

Not peptides at all

The book is titled The Complete Guide to Peptides, but several entries are not peptides: 5-Amino-1MQ (a small molecule), tesofensine (a small molecule reuptake inhibitor), MK-677 (a small molecule, which the book's own entry correctly notes is oral), L-carnitine (an amino acid derivative), and the "Lipo-B" and "Lipo-C" injections (vitamin and nutrient blends). The book acknowledges some of these are not peptides, but including them under a peptide banner, with the same format and the same confident dosing, blurs a line readers need to see clearly.

The Lipo entries also lean heavily on "detoxification" language. Your liver and kidneys detoxify you continuously. Vitamin injections do not detoxify anything in a measurable sense for someone who is not deficient.

The personas

The part of the book I found most concerning is the "Practical Usage and Regimen Examples" section. It invents five people and writes protocols for them.

John, 35, a competitive bodybuilder, is given CJC-1295, ipamorelin, IGF-1 LR3, AOD-9604 and BPC-157. Several of these are prohibited in tested sport. The book does not mention this in his persona.

Sarah, 45, with Hashimoto's thyroiditis and rheumatoid arthritis, is given thymulin injections, a thyroid bioregulator, BPC-157 and TB-500. These are two serious autoimmune diseases usually managed with carefully monitored medication. A protocol of unapproved immune-modulating injections, with no mention of her existing treatment or her rheumatologist, is not a responsible example to publish.

Mike, 60, an executive, is given Cerebrolysin by intramuscular injection twice a week for "cognitive enhancement", along with a cardiac bioregulator and other compounds.

These are presented as examples, not prescriptions. But a reader in Sarah's situation will see a protocol written for someone exactly like them.

The steelman

To be fair: the book is consistent about recommending medical consultation, it cautions about sourcing and legality, its maths chapter is correct, its approved drug entries are mostly accurate, its myths section is sensible, and it gives readers search terms to check its claims. Some readers will come away better informed than they started.

The takeaway

Treat this book as a map of names, not a guide to use. It is good for learning what exists, what category it belongs to, and what to search for. It is not a reliable source of dosing, safety or medical advice, and it tells you so itself, if you read the disclaimer at the top of the bioregulator chapter.

When a guide's numbers come from a shop, the guide is working for the shop. Your numbers should come from somewhere better: approved labels and human trials for anything you consider taking, and above all from your own body. Train consistently, eat for your goals, find and fix your deficiencies with proper bloodwork, and check for inherited conditions where there is reason to. Someone with that foundation in place, and their own results in hand, is very hard to mislead.

This series reviews a consumer book, not a clinical guideline. Many compounds it discusses are not approved for human use in most countries. Nothing here is medical advice or a recommendation to use any substance. Speak to a qualified clinician before starting anything.